Viking's GLP-1 candidate VK2735 is currently in multiple clinical trials. The company is assessing whether VK2735 can be administered monthly for maintenance dosing; this is a development-stage pipeline update with limited immediate market impact.
Viking's GLP-1 candidate VK2735 is currently in multiple clinical trials. The company is assessing whether VK2735 can be administered monthly for maintenance dosing; this is a development-stage pipeline update with limited immediate market impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
neutral
Sentiment Score
0.00
